NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL), a notable manufacturer of healthcare and consumer products, has announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET. The conference aims to provide updates on an ongoing transaction with Celularity Inc. Notably, NEXGEL has indicated that it will not proceed with financing through the previously established Securities Purchase Agreement with a certain institutional investor, raising concerns about the potential closure of the Celularity deal.
The company is pursuing a new financing structure and is in talks with different investors, as it seeks to navigate the complexities surrounding the Celularity transaction. During the conference call, NEXGEL plans to share further insights about the proposed transaction and updated strategic directions.
NEXGEL is recognized for its innovative healthcare solutions, particularly its high-water-content hydrogel products designed for both healthcare and consumer applications. The company has developed a range of well-known brands, including SilverSeal® and Turfguard®, and has established meaningful manufacturing relationships within the healthcare sector.
The upcoming conference call will be accessible via a toll-free number for U.S. callers and an international line, with a webcast available for broader audience reach. Stakeholders are advised to monitor this event closely as it could significantly impact NEXGEL’s operational strategy and market position.
In the press release, NEXGEL also included forward-looking statements regarding potential outcomes of the Celularity transaction and other operational outlooks. The company cautions that these statements involve inherent risks and uncertainties that could lead to actual results diverging from current anticipations. For more detailed risks, investors are encouraged to review the company’s Annual Report filed with the SEC.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) recently announced a rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET, to discuss progress with the proposed transaction involving Celularity Inc. The company clearly states that while they are progressing with negotiations for this deal, there is no guarantee of its closure. This uncertainty could introduce volatility in NEXGEL's stock price leading up to the update.
A pivotal aspect to consider is the change in financing plans. NEXGEL's previous agreement with an institutional investor will not be pursued, and the company is instead seeking a new financing structure with different investors. This strategic pivot could reflect a more favorable negotiating position or a reaction to market conditions, which suggests potential implications for investor sentiment.
Investors may want to leverage the upcoming conference call as an opportunity to evaluate management's insights regarding the transaction's viability. It’s essential to analyze not just the announcement itself but the accompanying narrative regarding the rationale behind the changes, which may give clarity on NEXGEL’s long-term growth trajectory.
Another factor to consider is NEXGEL’s diversified portfolio in the healthcare, beauty, and OTC industries, which could cushion any adverse impacts from the uncertainty surrounding the Celularity transaction. Should the deal materialize successfully, it may provide a significant boost to NEXGEL's product offerings and market share.
Investors should remain vigilant and follow the press release closely on April 23. Understanding the details of the proposed transaction, its financial structuring, and any potential risks outlined by management will be critical for making informed investment decisions. As always, weighing NEXGEL’s fundamentals against broader market trends will serve as a prudent strategy amid this period of uncertainty.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET.
While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a different group of investors under a new financing structure. The Company anticipates providing additional details regarding this proposed transaction with Celularity Inc. on April 23rd.
Shareholder Update Conference Call Details:
Date: April 23, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “attempt,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ**
How does the potential decrease in investor financing for NEXGEL impact the future valuation of the NexGel Inc Warrant NXGLW, especially in relation to the pending transaction with Celularity Inc.?
What specific details will NEXGEL provide during the April update regarding the NexGel Inc Warrant NXGLW and its implications for current shareholders?
Given the strategic pivot in financing, how might this affect the performance of NexGel Inc Warrant NXGLW if the Celularity transaction does not close as anticipated?
What risks does NEXGEL foresee in relation to the NexGel Inc Warrant NXGLW in light of the uncertainties surrounding the new investor agreement and the proposed transaction?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:
